Tokyo Tape
Sign in
← Falco Holdings

Quarterly report · Q1

4671.TEDINET S100OZLA
Period2022-04-01 → 2022-06-30
Filed2022-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 34
MetricValuePeriodScopeSource row
Revenue¥11.6bn2022-04-01 → 2022-06-30Cons.Net sales
Revenue¥50.0bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥12.0bn2021-04-01 → 2021-06-30Cons.Net sales
Operating income¥681m2022-04-01 → 2022-06-30Cons.Operating income
Operating income¥1.3bn2021-04-01 → 2021-06-30Cons.Operating income
Ordinary income¥769m2022-04-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥5.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥1.3bn2021-04-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥748m2022-04-01 → 2022-06-30Cons.Income before income taxes
Profit before tax¥1.3bn2021-04-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥442m2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥3.5bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥845m2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥442m2022-04-01 → 2022-06-30Cons.Profit loss
Net income¥845m2021-04-01 → 2021-06-30Cons.Profit loss
Total assets¥38.2bnat 2022-06-30Cons.Assets
Total assets¥40.3bnat 2022-03-31Cons.Assets
Total assets¥37.7bnat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥14.6bnat 2022-06-30Cons.Liabilities
Total liabilities¥16.8bnat 2022-03-31Cons.Liabilities
Net assets / equity¥23.6bnat 2022-06-30Cons.Net assets
Net assets / equity¥23.5bnat 2022-03-31Cons.Net assets
Net assets / equity¥21.0bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥9.6bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥10.6bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥42.322022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥3392021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥81.412021-04-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥42.252022-04-01 → 2022-06-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥336.992021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥81.282021-04-01 → 2021-06-30Cons.Diluted earnings per share (5-year summary)
Equity ratio61.5%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio58.1%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio55.5%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥4m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥4m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥108m
jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥7.7bn
jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥7.7bn
jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥3m
jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥782m
jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥3.9bn
jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥3.9bn
jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥0
jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥6m
—segment totalrevenue2022-04-01 → 2022-06-30¥11.6bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥11.6bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥4m
—segment totalsegment profit2022-04-01 → 2022-06-30¥789m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-06-30−¥4m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-06-30−¥4m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-06-30−¥84m
jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥8.0bn
jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥8.0bn
jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥3m
jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥1.3bn
jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥4.0bn
jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥4.0bn
jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥0
jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥102m
—segment totalrevenue2021-04-01 → 2021-06-30¥12.0bn
—segment totalrevenue external2021-04-01 → 2021-06-30¥12.0bn
—segment totalrevenue intersegment2021-04-01 → 2021-06-30¥4m
—segment totalsegment profit2021-04-01 → 2021-06-30¥1.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 352
ItemContextValueUnit
Extraordinary lossPrior1YTDDuration11000000JPY
Extraordinary lossCurrentYTDDuration21000000JPY
Income before income taxesPrior1YTDDuration1338000000JPY
Income before income taxesCurrentYTDDuration748000000JPY
Income taxes currentPrior1YTDDuration490000000JPY
Income taxes currentCurrentYTDDuration289000000JPY
Income taxes deferredPrior1YTDDuration2000000JPY
Income taxes deferredCurrentYTDDuration16000000JPY
Income taxesPrior1YTDDuration493000000JPY
Income taxesCurrentYTDDuration305000000JPY
Profit lossPrior1YTDDuration845000000JPY
Profit lossCurrentYTDDuration442000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration845000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration442000000JPY
Profit lossPrior1YTDDuration845000000JPY
Profit lossCurrentYTDDuration442000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration-52000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration52000000JPY
Other comprehensive incomePrior1YTDDuration-52000000JPY
Other comprehensive incomeCurrentYTDDuration52000000JPY
Comprehensive incomePrior1YTDDuration792000000JPY
Comprehensive incomeCurrentYTDDuration495000000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration792000000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration495000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E04982-000ClinicalTestingBusinessReportableSegmentsMember8029000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember3992000000JPY
Revenues from external customersPrior1YTDDuration_ReportableSegmentsMember12021000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration12021000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E04982-000ClinicalTestingBusinessReportableSegmentsMember3000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember0JPY
Transactions with other segmentsPrior1YTDDuration_ReportableSegmentsMember4000000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-4000000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E04982-000ClinicalTestingBusinessReportableSegmentsMember8033000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember3992000000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember12025000000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-4000000JPY
Net salesPrior1YTDDuration12021000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E04982-000ClinicalTestingBusinessReportableSegmentsMember1259000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember102000000JPY
Operating incomePrior1YTDDuration_ReportableSegmentsMember1362000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember-84000000JPY
Operating incomePrior1YTDDuration1277000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E04982-000ClinicalTestingBusinessReportableSegmentsMember7674000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember3891000000JPY
Revenues from external customersCurrentYTDDuration_ReportableSegmentsMember11566000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration11566000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E04982-000ClinicalTestingBusinessReportableSegmentsMember3000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass